Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Mathilde Hunault, Cécile Pautas, Sarah Bertoli...
https://pubmed.ncbi.nlm.nih.gov/40552969/Actively Recruiting
Led by University Hospital, Angers · Updated on 2026-07-17
3100
Participants Needed
56
Research Sites
335 weeks
Total Duration
This trial studies adults aged 18 to 60 with Acute Myeloid Leukemia AML to improve overall survival using risk-adapted treatment strategies. It is an open-label, multicenter phase IIIII study evaluating different chemotherapy regimens during induction, consolidation, and, when applicable, stem cell transplantation. The study also assesses graft versus host disease GvHD prevention methods after transplant in intermediate-risk patients. Participants receive one of several chemotherapy induction regimens comparing daunorubicin and high-dose idarubicin combined with cytarabine. Consolidation treatment compares high-dose versus intermediate-dose cytarabine, sometimes combined with drugs like vosaroxin, dexamethasone, or venetoclax. For patients receiving allogeneic stem cell transplant, GvHD prophylaxis is studied comparing standard treatments such as methotrexate and cyclosporine with mycophenolic acid combinations. Treatment cycles and doses vary based on the patients risk and response. Throughout the study, participants undergo bone marrow evaluations, blood tests, and heart function assessments to monitor response and safety. Researchers track overall survival over three years, incidence of acute GvHD within 100 days post-transplant, and disease-free survival at 18 months. Participants provide informed consent and are monitored regularly during treatment and follow-up periods. The study completion is planned for January 2032.
CONDITIONS
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
M
Mathilde Hunault, PD
D
DRCI Promotion Interne
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Angers
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 to 7 days for induction cycle
Participants receive induction chemotherapy with either daunorubicin or high-dose idarubicin combined with cytarabine. Bone marrow tests are done on Day 15 to assess response.
Multiple visits including bone marrow aspirate on Day 15
Duration - Up to 3 cycles, each lasting several days
Participants receive consolidation chemotherapy with either high-dose or intermediate-dose cytarabine, sometimes combined with other drugs like vosaroxin, dexamethasone, or venetoclax. Up to three courses are given based on risk and response.
Multiple visits for chemotherapy administration and monitoring
Duration - Up to 100 days post-transplant
Participants undergoing allogeneic stem cell transplant receive GvHD prevention treatment with different drug combinations such as methotrexate, cyclosporine, and mycophenolic acid, depending on their risk group and transplant conditioning regimen.
Regular visits to monitor for GvHD and side effects
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
14
Have more questions? Get in touch with our team for quick support
Mathilde Hunault, Cécile Pautas, Sarah Bertoli...
https://pubmed.ncbi.nlm.nih.gov/40552969/Nicolas Duployez, Romane Joudinaud, Augustin Boudry...
https://pubmed.ncbi.nlm.nih.gov/42166362/University Hospital, Angers
Lead Sponsor